ASCO® 2023 Insights: "BELLWAVE-003 - A Phase 2 Dose Escalation, Confirmation, and Cohort Expansion Study of Nemtabrutinib in Hematologic Malignancies"

0 views
June 14, 2023
Comments 0
Login to view comments. Click here to Login